Cargando…
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
Chimeric antigen receptor–associated hemophagocytic lymphohistiocytosis (HLH)–like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report p...
Autores principales: | McNerney, Kevin O., Si Lim, Stephanie J., Ishikawa, Kyle, Dreyzin, Alexandra, Vatsayan, Anant, Chen, John J., Baggott, Christina, Prabhu, Snehit, Pacenta, Holly L., Philips, Christine, Rossoff, Jenna, Stefanski, Heather E., Talano, Julie-An, Moskop, Amy, Verneris, Michael, Myers, Doug, Karras, Nicole A., Brown, Patrick, Bonifant, Challice L., Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, Christa, Keating, Amy K., Baumeister, Susanne H. C., Fabrizio, Vanessa A., Chinnabhandar, Vasant, Egeler, Emily, Mavroukakis, Sharon, Curran, Kevin J., Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275701/ https://www.ncbi.nlm.nih.gov/pubmed/36857419 http://dx.doi.org/10.1182/bloodadvances.2022008893 |
Ejemplares similares
-
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022) -
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022) -
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
por: Barsan, Valentin, et al.
Publicado: (2023) -
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022) -
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)